$LOMA

Loma Negra Reports 2Q26 results

Loma Negra (NYSE: LOMA, BYMA: LOMA) reported 2Q26 results for the quarter ended June 30, 2026. Net sales rose 2.1% YoY to Ps. 238,053 million (US$166 million). Consolidated adjusted EBITDA fell 2.5% YoY to Ps. 48,175 million (US$38 million), with margin down to 20.2%. Net profit increased to Ps. 7,043 million. Net debt was Ps. 273,650 million (US$185 million).

Original reporting
Published Aug 6, 2026, 10:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 10:19 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$LOMA
Neutral
medium confidence
Mentioned
$LOMA
Relevance
8/10
alphai data visualization · based on prnewswire.com
Decision brief

The 30-second read

$LOMANeutralMed
01

Why it matters

Traders can reassess near-term earnings power using the disclosed mix of (1) volume softness, (2) margin compression, (3) cost inflation drivers (depreciation, packaging, maintenance, freight, seasonal kiln shutdown planning), and (4) leverage improvement (net debt/EBITDA down to 1.30x).

02

Market read

The print combines a sharp net profit rebound with weaker EBITDA margin and lagging volumes, creating a mixed setup for valuation and near-term positioning.

03

What to watch

Unit costs rose in cement (unit costs +5.4% YoY vs pricing +3.6%), and SG&A jumped 15.7% YoY, both of which can pressure future EBITDA even if top-line holds.

Relevance 8/10Novelty 8/10Timing: after-hours earnings release, Aug. 6, 2026

Background

Loma Negra is Argentina’s leading cement producer and reported 2Q26 financial and operating results for the quarter ended June 30, 2026.

Company-level read

Ticker impact

$LOMANeutralMedium confidence
Context

Loma Negra reported 2Q26 results, including net profit rising to Ps. 7,043 million and Adjusted EBITDA margin falling to 20.2%.

Expected impact

Likely modest, two-sided reaction: upside from net profit surge and higher dollar EBITDA, offset by margin decline and volume softness.

Evidence & confidence

The release provides multiple decision-relevant datapoints (profit, EBITDA, margin, net debt leverage, segment volume trends). However, it is a single-quarter print without explicit forward guidance or consensus context in the excerpt, limiting conviction on magnitude/direction.

Market effects

Cement demand recovery appears gradual, with heavy-rain disruption cited for April and bagged cement lagging retail/self-construction.

Argentina construction and public works demand looks uneven, with concrete and aggregates volumes down while railroad volumes rose.

Limited direct global read-through, but dollar-denominated EBITDA improvement may matter for cross-border investors tracking FX-adjusted cash generation.

Counterpoint

The net profit jump may be driven by lower financial costs rather than operating strength, so equity upside could fade if margins and volumes do not stabilize.

Key entities

  • Loma Negra

    Reported 2Q26 net sales, Adjusted EBITDA, net profit, net debt, and segment volume and cost drivers.

  • Sergio Faifman

    CEO commentary attributed weak April to heavy rains and described gradual demand recovery into 2H26.

Related articles

$DRIMedAI 8/10

DRI Healthcare Reports Second Quarter 2026 Results and New Board Appointment

DRI Healthcare Trust (TSX: DHT.UN, DHT.U) reported Q2 2026 results for the quarter ended June 30, 2026: total income $50.1M, total cash receipts $46.5M, and adjusted EBITDA $42.6M. It repurchased 89,513 units at $11.65 and paid a $0.11/unit distribution. After quarter-end, it exercised a put option on Ekterly for about $178M and received FDA approval for Lumvoa (veligrotug), triggering $75M milestone payments.

$LGNDMed

Ligand Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary

Ligand Pharmaceuticals reported Q2 2026 results and discussed its XOMA Royalty acquisition, adding 120+ assets and extending cash flow duration through 2040. Management cited 32% YoY royalty revenue growth and expects 2026 royalty revenue of $225M-$250M with cash opex halved since 2022. Ligand issued a $700M zero-coupon convertible, raised 2026 adjusted EPS guidance to $9.00-$9.50, and expects accretion from XOMA in 2H26 and 2027.

$KDPMed

Keurig Dr Pepper Inc. Q2 2026 Earnings Call Summary

Keurig Dr Pepper reported Q2 2026 results that exceeded expectations, citing double-digit U.S. Refreshment Beverages growth and day-one integration of JDE Peet's. Dr Pepper Zero Sugar grew 30% in retail sales and energy reached 9% market share. U.S. Coffee faced margin pressure from hedging and tariffs. KDP reaffirmed low double-digit EPS growth for 2026 and low-double-digit legacy growth at the high end of 4% to 6%.

$TAPMed

Molson Coors Beverage Company Q2 2026 Earnings Call Summary

Molson Coors reported Q2 2026 volume pressure tied to an energy and inflation shock after conflict in Iran, plus stronger promotions and geopolitical uncertainty in EMEA and APAC. The company reaffirmed FY2026 guidance, citing improving U.S. industry volumes, 1% to 2% annual U.S. price increases, and Midwest Premium aluminum COGS above $130 million, partly hedged. It also outlined a $450 million cost-savings plan and Atomic Brands integration.

$ITTMed

ITT Inc. Q2 2026 Earnings Call Summary

ITT Inc. reported Q2 2026 results driven by 13% organic revenue growth, including 17% at CCT and 21% at Flow Technologies. Full-year organic revenue guidance was raised to 5% to 8% and margin expansion of over 100 bps is expected. Management cited SPX FLOW integration synergies, $71m one-time acquisition costs, and Middle East order delays.